Skip to main content
Matinas BioPharma Holdings, Inc. logo

Matinas BioPharma Holdings, Inc. — Investor Relations & Filings

Ticker · MTNB ISIN · US5768101058 LEI · 549300TGHXVKQ7EJRO41 US Professional, scientific and technical activities
Filings indexed 548 across all filing types
Latest filing 2026-05-08 Interim / Quarterly Rep…
Country US United States of America
Listing US MTNB

About Matinas BioPharma Holdings, Inc.

https://www.matinasbiopharma.com/

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics using its proprietary Lipid Nanocrystal (LNC) platform. This technology is designed to enable the safe, oral, and targeted intracellular delivery of a variety of molecules, including small molecules, nucleic acids, and small oligonucleotides. The company's lead product candidate, MAT2203, is an oral formulation of the antifungal drug amphotericin B. Matinas is also advancing discovery programs directed at oncology and inflammation.

Recent filings

Filing Released Lang Actions
10-Q - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)
Regulatory Filings
2026-04-03 English
8-K Filing
Regulatory Filings
2026-01-23 English
8-K
Regulatory Filings
2025-12-12 English
8-K
Regulatory Filings
2025-11-21 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-11-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.